Dr reddys laboratories ltd (RDY)
CashFlow / Yearly
Mar'18
Cash flows from/(used in) operating activities:
Profit for the year

151,000

Adjustments for:
Income tax expense

70,000

Dividend and profit on sale of investments

35,000

Depreciation and amortization

180,000

Impairment loss on property, plant and equipment and other intangible assets

1,000

Inventory write-downs

45,000

Allowance for doubtful trade and other receivables

-2,000

Loss/(profit) on sale of property, plant and equipment and other intangible assets, net

-1,000

Allowance for sales returns

41,000

Share of profit of equity accounted investees

5,000

Exchange (gain)/loss, net

-5,000

Exchange loss related to Venezuela operations

0

Interest (income)/expense, net

4,000

Equity settled share-based payment expense

7,000

Changes in operating assets and liabilities:
Trade and other receivables

-32,000

Inventories

-50,000

Trade and other payables

38,000

Other assets and other liabilities

-94,000

Cash generated from operations

319,000

Income tax paid

42,000

Net cash from operating activities

277,000

Cash flows from/(used in) investing activities:
Expenditures on property, plant and equipment

143,000

Proceeds from sale of property, plant and equipment

2,000

Expenditures on other intangible assets

27,000

Investment in equity accounted investees

0

Purchase of other investments

1,051,000

Proceeds from sale of other investments

984,000

Cash paid for acquisition of business, net of cash acquired

0

Interest and dividend received

6,000

Net cash used in investing activities

-229,000

Cash flows from/(used in) financing activities:
Proceeds from issuance of equity shares

0

Buyback of equity shares

0

Proceeds from/(repayment of) short term borrowings, net

-277,000

Proceeds from/(repayment of) long term borrowings, net

290,000

Dividend paid (including corporate dividend tax)

61,000

Interest paid

20,000

Net cash used in financing activities

-68,000

Net increase/(decrease) in cash and cash equivalents

-20,000

Effect of exchange rate changes on cash and cash equivalents

1,000

Supplemental schedule of non-cash investing and financing activities:
Investment in shares of Curis, Inc.

0

Acquisition of select products portfolio of UCB

0

Property, plant and equipment and intangibles purchased on credit during the year, including contingent consideration on purchase of intangibles

10,000

Property, plant and equipment purchased under capital lease

0